Risk of Non–Hodgkin Lymphoma Associated with Polymorphisms in Folate-Metabolizing Genes

  1. Tracy J. Lightfoot1,
  2. Christine F. Skibola4,
  3. Eleanor V. Willett1,
  4. Danica R. Skibola4,
  5. James M. Allan2,
  6. Fabio Coppede4,
  7. Peter J. Adamson1,
  8. Gareth J. Morgan3,
  9. Eve Roman1 and
  10. Martyn T. Smith4
  1. Epidemiology and Genetics Unit, Departments of 1Health Sciences and 2Biology, University of York, York; and 3Institute of Cancer Research and Royal Marsden NHS Trust, Department of Haemato-Oncology, Surrey, United Kingdom; and 4Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, California
  1. Requests for reprints:
    Tracy Lightfoot, Epidemiology and Genetics Unit, Department of Health Sciences, University of York, Area 3, Seebohm Rowntree Building YO10 5DD, York, United Kingdom. Phone: 44-1904-321881; Fax: 44-1904-321899. E-mail: tracy.lightfoot{at}egu.york.ac.uk

Abstract

Genetic instability, including chromosomal imbalance, is important in the pathogenesis of lymphoproliferative disorders such as non–Hodgkin lymphoma (NHL). DNA synthesis and methylation, which are closely linked to folate metabolism and transport, may be affected by polymorphisms in genes involved in these pathways. Folate metabolism polymorphisms have been linked to acute lymphoblastic leukemia and colorectal cancer. To evaluate whether genetic variation in folate metabolism and transport may have a role in determining the risk of developing NHL, we analyzed several polymorphisms using DNA obtained as part of a large U.K. population-based case-control study of lymphoma. Polymorphisms studied include methylenetetrahydrofolate reductase (MTHFR) 677 C>T and 1298 A>C, methionine synthase (MTR) 2756 A>G, serine hydroxymethyltransferase (SHMT1) 1420 C>T, thymidylate synthase (TYMS) 1494del6 and 28–bp repeat, and reduced folate carrier (RFC) 80 G>A. Increased risks for NHL [odds ratio (OR), 1.48; 95% confidence intervals (CI), 1.12-1.97], and marginal zone lymphoma (OR, 3.38; 95% CI, 1.30-8.82) were associated with the TYMS 2R/3R variant. Marginal increased risks were also observed for diffuse large B cell lymphoma with the TYMS homozygous 6 bp deletion (OR, 1.61; 95% CI, 0.99-2.60) and for follicular lymphoma with RFC 80AA (OR, 1.44; 95% CI, 0.94-2.22) and TYMS 28–bp repeat 2R/3R (OR, 1.45; 95% CI, 0.96-2.2). We observed no association between NHL and haplotypes for MTHFR or TYMS. These findings are somewhat inconsistent with those of others, but may reflect differences in circulating folate levels between study populations. Thus, further investigations are warranted in larger series with dietary information to determine the roles that genetics and folic acid status play in the etiology of lymphoma. (Cancer Epidemiol Biomarkers Prev 2005;14(12):2999–3003)

Footnotes

  • Grant support: Leukemia Research of Great Britain, NIH grant RO1-CA104862 from the U.S. National Cancer Institute (M.T. Smith, P.I.) and by the National Foundation for Cancer Research.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted September 26, 2005.
    • Received July 22, 2005.
    • Revision received September 16, 2005.
« Previous | Next Article »Table of Contents